Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer.

Divgi C.

Semin Nucl Med. 2011 Sep;41(5):369-73. doi: 10.1053/j.semnuclmed.2011.05.004. Review.

PMID:
21803187
2.

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB.

Clin Endocrinol (Oxf). 2001 Jul;55(1):47-60.

PMID:
11453952
3.

131I-MIBG therapy of neural crest tumours (review).

Troncone L, Rufini V.

Anticancer Res. 1997 May-Jun;17(3B):1823-31. Review.

PMID:
9179240
4.

The role of external beam radiation and targeted therapy in thyroid cancer.

Brierley J, Sherman E.

Semin Radiat Oncol. 2012 Jul;22(3):254-62. doi: 10.1016/j.semradonc.2012.03.010. Review.

PMID:
22687950
5.

Drug therapy alternatives in the treatment of thyroid cancer.

O'Doherty MJ, Coakley AJ.

Drugs. 1998 Jun;55(6):801-12. Review.

PMID:
9617595
6.

Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.

Juweid ME, Hajjar G, Stein R, Sharkey RM, Herskovic T, Swayne LC, Suleiman S, Pereira M, Rubin AD, Goldenberg DM.

J Nucl Med. 2000 Jan;41(1):93-103.

7.

Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.

Fullerton NE, Boyd M, Ross SC, Pimlott SL, Babich J, Kirk D, Zalutsky MR, Mairs RJ.

Med Chem. 2005 Nov;1(6):611-8.

PMID:
16787344
8.

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.

Clin Cancer Res. 2000 Oct;6(10):3855-63.

9.
10.

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.

Wiseman GA, Kvols LK.

Semin Nucl Med. 1995 Jul;25(3):272-8. Review.

PMID:
7570046
11.

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.

Juweid ME, Hajjar G, Swayne LC, Sharkey RM, Suleiman S, Herskovic T, Pereira M, Rubin AD, Goldenberg DM.

Cancer. 1999 Apr 15;85(8):1828-42.

PMID:
10223579
12.

Radionuclide therapy of neural crest tumors.

Voûte PA, Hoefnagel CA, de Kraker J, Evans AE, Hayes A, Green A.

Med Pediatr Oncol. 1987;15(4):192-5.

PMID:
3657706
13.
14.

Systemic radiation therapy with unsealed radionuclides.

McDougall IR.

Semin Radiat Oncol. 2000 Apr;10(2):94-102. Review.

PMID:
10727598
15.

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.

Cancer Res. 1999 Jun 1;59(11):2635-43.

16.

Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.

Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.

J Nucl Med. 1997 Mar;38(3):409-18.

17.

Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.

Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK.

Radiother Oncol. 2008 Oct;89(1):105-13. doi: 10.1016/j.radonc.2008.05.023. Epub 2008 Jun 23.

PMID:
18579244
18.

Targeted therapy in radioiodine refractory thyroid cancer.

Pacini F, Brilli L, Marchisotta S.

Q J Nucl Med Mol Imaging. 2009 Oct;53(5):520-5. Review.

19.

Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm.

DeNardo G, DeNardo S.

Semin Nucl Med. 2010 Mar;40(2):136-44. doi: 10.1053/j.semnuclmed.2009.10.005. Review.

PMID:
20113681
20.

Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers.

Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI, Zhang ZF.

Cancer Lett. 2006 Jul 8;238(1):42-52. Epub 2005 Jul 21.

PMID:
16039041

Supplemental Content

Support Center